Intec Pharma recently released the results from two pharmacokinetic (PK) studies of AP-CDLD (n=18 and n=30). The data showed trends towards lower peak serum concentrations (Cmax) and a longer half-life (T1/2, although there was some inconsistency), which should reduce dyskinesia and off-time, respectively. Additionally, one study measured food effect, which was present but did not delay onset of effects, unlike the approved extended-release carbidopa/levodopa formulation, Rytary.
21 May 2018
Bolstering the case for AP-CDLD
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Bolstering the case for AP-CDLD
Indaptus Therapeutics, Inc. (INDP:NAS) | 0 0 0.0%
- Published:
21 May 2018 -
Author:
Maxim Jacobs -
Pages:
6
Intec Pharma recently released the results from two pharmacokinetic (PK) studies of AP-CDLD (n=18 and n=30). The data showed trends towards lower peak serum concentrations (Cmax) and a longer half-life (T1/2, although there was some inconsistency), which should reduce dyskinesia and off-time, respectively. Additionally, one study measured food effect, which was present but did not delay onset of effects, unlike the approved extended-release carbidopa/levodopa formulation, Rytary.